ArticleHLA2026

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

Haiqiong Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.